CISATRACURIUM BESYLATE

Post-LOE

cisatracurium besylate

Pfizer

ANDAINJECTIONINJECTABLE

Approved

Mar 2018

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

CISATRACURIUM BESYLATE (cisatracurium besylate) by Pfizer is end-plate to antagonize the action of acetylcholine, resulting in blockade of neuromuscular transmission. Approved for an adjunct to general anesthesia to facilitate tracheal intubation. First approved in 2018.

Drug data last refreshed 21h ago

Mechanism of Action

end-plate to antagonize the action of acetylcholine, resulting in blockade of neuromuscular transmission. This action is antagonized by acetylcholinesterase inhibitors such as neostigmine.

Indications (1)

an adjunct to general anesthesia to facilitate tracheal intubation

Company

Worked on CISATRACURIUM BESYLATE at Pfizer? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.